the N-dealkylated tolterodine. The remainder of population is referred to as the “extensive metabolizers.” Pharmacokinetic studies revealed tolterodine is metabolized at the slower rate in poor metabolizers when compared to extensive metabolizers; these results in higher serum concentrations of the tolterodine and negligible concentrations of 5-HMT.
Excretion:
Following administration of 5 mg oral dose of tolterodine solution to healthy volunteers, in urine 77% of radioactivity was recovered and in feces 17% was recovered in 7 days. As intact tolterodine less than 1% (< 2.5% in poor metabolizers) of the dose was recovered, and 5% to 14% (< 1% in poor metabolizers) was recovered as 5-HMT.
A summary of the mean (± standard deviation) pharmacokinetic parameters, tolterodine extended release and the 5HMT in poor (PM) and extensive (EM) metabolizers is provided. These data was obtained following multiple and single doses of tolterodine extended release were administered daily to the 17 healthy male volunteers (4 PM, 13 EM).
2.5 Drug Interactions:(7)
Potent CYP2D6 inhibitors:
Fluoxetine is selective serotonin reuptake inhibitor and potent inhibitor of CYP2D6 activity. It was observed that the fluoxetine significantly inhibits metabolism of the tolterodine immediate release in an extensive metabolizers, resulting in the increase in tolterodine AUC. There was 52% decrease in Cmax and 20% decrease in the AUC of 5-hydroxymethyl tolterodine. The sum of unbound serum concentrations
The absorption of drugs differ in the elderly than they do in adults. Absorption primary occurs in the gastrointestinal system. The pH in the gastro intestinal system is higher because of the reduction in acid production in the stomach. Emptying is also decreased; this does not allow the drug to move on further into the system to be absorbed. Blood flow to the gastrointestinal system is reduced by 40-50% because of the decrease in cardiac output and decreased perfusion. The reduction of blood flow causes the villi in the stomach lining to become blunt and flattened. The reduction in blood flow and surface area results in the decreased absorption of drugs. (Lilley, Collins, and Snyder
While the codeine is what caused the CNS depression that threatened our patient, it should be noted that the ineffectiveness of his SSRI he spoke of in our review of systems may also be attributed to our patient’s possible status as an ultra-metabolizer. Fluoxetine, fluvoxamine, and paroxetine are influenced by a few genes of the CYP450 enzymes but none more than CYP2D6. The ultra-metabolizer phenotype of CYP2D6 causes the patient to have sub-therapeutic concentrations of SSRIs causing decreased response.
Selective serotonin reuptake inhibitors (SSRIs) have been prescribed by physicians for many years now. One reason SSRIs are so popular is because of the many mental disorders they can be used for such as anxiety, depression, obsessive-compulsive disorder (OCD), phobias, and many more (Weitzel & Jiwanlal, 2001). The four major types of SSRIs that are most commonly used by people with mental disorders are fluoxetine (Prozac), paroxetine (Paxil), sertraline (Zoloft), and citalopram hydrobromide (Celexa); SSRIs work on the brain by acting on the reuptake pathway of serotonin (Stone, 2010). There are some advantages for taking SSRIs. One advantage is that SSRIs have fewer side effects than most of the other antidepressant medications such as monoamine oxidase inhibitors (MAOIs) and tricyclics (Weitzel & Jiwanlal, 2001). Another advantage is that SSRIs have less of a risk of toxicity in overdose (Lane, Baldwin, & Preskorn, 1995). SSRIs are better tolerated than tricyclic antidepressant medication because they cause less sedation and problematic anticholinergic effects. There are also reports indicating that SSRIs have fewer negative effects on the cardiovascular system than tricyclic antidepressants (Edwards, 1992).
With an estimated 9.3% of Americans currently living with major depression or bipolar disorder, according to the NIMH, the safety of antidepressant drugs is at the forefront of many pharmaceutical discussions. At present, the most common drugs used to treat the debilitating lethargy, anxiety, and fatigue often associated with major depression fall into three key categories based upon mechanism of action: SSRIs, Tricyclics, and MAOIs. Since major depression and bipolar disorder are characterized by imbalances of certain chemicals within the brain, prescription medications are often the best way of relieving the symptoms of these disorders. As with any medication, antidepressants carry risks of side-effects, which usually relate to the drug
The acute crisis of metabolic decompensation in MSUD is a deadly dangerous medical case that demands immediate action to lower concentrations of leucine and other BCAA in plasma. This aim can be reached by using Intravenous mixtures of amino acids , which deals with the process of protein synthesis , however these mixtures are not generally available and requires medical care and continuous administration , that what lead to developing enteral mixtures suitable for administration by nasogastric drip in minimal volume along with provision of water and calories intravenously , to reduce concentration of Lucien and other BCAA in patients with acute crisis of metabolic decompensation in MSUD. This way proved
While many selective serotonin reuptake inhibitors (SSRI’s) are accepted as first line treatments for depression and anxiety, they differ greatly in their chemical structure and pharmacokinetic profile. These differences are especially important when selecting the appropriate antidepressant drug for the client. It is also important to understand the different drug interactions and pharmacological profiles when considering an SSRI for a patient as well.
This drug after oral administration is well absorbed (80%-90%), and distributed widely throughout the body, except the brain. Furthermore, is metabolized in the liver to oxypurinol and excreted unchanged in the urine after approximately 6 hours after ingestion, with a half-life of 2-3 hours. During administration of allopurinol, caution should be used with renal impairment patients and renal function test should be performed to determine the appropriate dosage. Hepatotoxicity is also associated with this drug, therefore it should not be given to patients with severe liver
It is also known to cause drug interaction in dose dependence manner, single and multiple dose of 30mg did not affect the elimination or area under the curve (AUC) of diazepam 10mg, tolbutamide 1000mg or chlorothiazide 500mg, or of secobarbitone (secobarbital) 150mg, but 60mg prolonged the elimination of diazepam, but physiological responses to diazepam were unaffected (3). Also, fluoxetine might have enhanced the toxic effects of other drugs, such as, cocaine because of its weak pro-arrhythmogenic properties (10). Therefore, the concentration of fluoxetine and norfluoxetine is important.
When Lilly Research Laboratories were developing and screening naphtaheleneyloxy – arylprpylamines series, in August 2003, for serotonin and norepinephrine reuptake inhibitor, they found that Duloxetine, a member of this series, proved efficiency in treatment of major depression disorder , owing to Duloxetine is a balanced 5-hydroxytryptamine and norepinephrine dual reuptake inhibitor with minor inhibitory effect on dopamine. [1]
Prozac (fluoxetine) is a selective serotonin reuptake inhibitors (SSRI) antidepressant .Prozac is used to treat major depressive disorder. In 1970 the company Eli Lilly came up with the compound for Prozac. It was first tested as a treatment for high blood pressure, which worked in some animals but not human’s .It was also tested on psychotic patients and people in hospitals with depression by now given the generic name fluoxetine had no obvious benefit, with a number of patients getting worse. Finally it was tested on people with mild depressives. It was tested on five recruits all five started to show signs of cheering up by 1999. Depression was rarely discussed and antidepressants largely restricted people went to their GPs with anxiety
The dose-response curve in the presence of antagonist shows it effect on the ileum smooth muscle contraction which increases rapidly after 5 minutes exposure to atropine at a constant concentration of 3 x 10-7 M. The dose-response curve in the absence of antagonist shows it effect on the ileum smooth muscle contraction which increases rapidly on 3 minutes exposure to acetylcholine with the interval of 20 seconds between all doses at the concentration of 1 x 10-8 M to 1 x 10-4 M for every 3-2 doses. Also, as shown in figure 1, dose-response curve in the absence of antagonist has a higher contraction than the dose response curve in the presence of antagonist.
tested in rats for liver toxicity. Eleven of these drugs were shown to be toxic, while 17 were
Memantine is well absorbed orally with approximately 100% bioavailability. [1] It can be administered as an oral tablet or an oral liquid taken once daily. [2] Its peak plasma concentrations are reached after around 3 to 7 hours. Food has no effect on the absorption of the drug. The volume of distribution of this drug is 9 to 11 L/kg with a protein binding value of 45%. [1] The side effects of Memantine include pain, leg pain, fever and an increased appetite. Less common side effects include: vomiting, anxiety, hypertonia and cystitis. Some adverse reactions may include the following: dizziness, confusion, headache and tiredness.
Moreover, although in vivo studies of human intestinal drug metabolism could provide very informative data, these studies are very difficult to conduct due to several technical and ethical challenges. Thus, the availability of a reliable tool that can scale data from the in vitro setting to in vivo in humans by integrating IVIV extrapolation (IVIVE) to the appropriate human in vivo system using algorithms and physiologically relevant scaling factors might help overcome this drawback.
The concentration of Candesartan in plasma of each rat and the respective average values at different time intervals following the oral administration of pure Candesartan, Candesartan conventional capsule dosage form and Candesartan optimized formulation (Run 18) are given in Table 16. A comparative mean plasma concentration-time curve of pure Candesartan, Candesartan conventional capsule dosage form and Candesartan optimized formulation (Run 18) are illustrated in Fig.14. The mean pharmacokinetic parameters of the pure Candesartan, Candesartan conventional capsule dosage form and Candesartan optimized formulation (Run 18) were estimated from the in vivo experiments and the results are shown in the Table17--19 respectively.